Vaccine group Gavi seeks to broaden donor base as aid budgets shrink
By Ahmed Eljechtimi
RABAT (Reuters) -Global vaccine group Gavi is seeking new donors for its work funding childhood immunisation in the world's poorest countries, its chief executive told Reuters, as many traditional funders cut international aid budgets.
Gavi is aiming to raise $9 billion at a summit in Brussels later this month for its work from 2026-2030, but countries including the United States, the United Kingdom and France have all signalled that they plan to slash global aid funding in the coming years, and their pledges remain uncertain.
"We want to broaden our donor base," Gavi's Sania Nishtar told Reuters in Rabat, where she met officials to encourage Morocco to join as a new donor.
She said that India and Indonesia, which had previously been supported by Gavi, were now contributing as donors to the organization, which works with low and middle-income countries to buy vaccines for diseases from measles to cholera.
Other countries like Portugal have also increased their funding commitment, she said.
During her Morocco visit, Nishtar toured a vaccine manufacturing facility near Casablanca under development by Marbio, a biopharmaceutical venture backed by Morocco.
She said the plant had "a good chance" of benefiting from Gavi's $1.2 billion African Vaccine Manufacturing Accelerator, a scheme aimed at boosting vaccine production on the continent.
Gavi has already sought out more private sector donors, initiated cost-saving initiatives, and discussed closer collaboration with other global health groups as part of plans to try to tackle potential shortfalls in funding.
Nishtar said the organization was making contingency plans, but she hoped that donors at the June 25 summit would give enough that they would not be needed.
A U.S. government document showed in March that the U.S., which has previously given around $300 million to Gavi annually, did not plan any future funding.
Nishtar said that Gavi has not yet received this year's funding, which has already been approved by Congress.
Gavi is currently focused on combating a global measles outbreak and is responding to cholera outbreaks in Sudan, South Sudan, and Angola, where it has made special arrangements to supply vaccines from its stockpiles, Nishtar said.
It is also supporting Sierra Leone, where the spread of mpox has accelerated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
House votes to cut global health funding
The Big Story The House on Thursday narrowly passed a 'recissions' proposal to cancel $9.4 billion in money Congress already appropriated, including $900 million in funding for global health initiatives. Four Republicans voted against it. © AFP via Getty The vote codifies cuts championed by the Department of Government Efficiency, which was led by billionaire Elon Musk. It includes slashing $500 million of the $6 billion appropriated in fiscal year 2025 for global health programs like the President's Emergency Plan for AIDS Relief (PEPFAR) that are within the Department of State and $400 million of the $4 billion appropriated for USAID global health programs. Included in that plan is ending all funding for Gavi, a global program that purchases shots to help vaccinate children in developing countries against some of the world's deadliest diseases. PEPFAR is seen as one of the most successful U.S.-led international aid programs and has typically enjoyed bipartisan support. It's credited with having saved 26 million lives and enabling 7.8 million babies to be born without HIV infection. Global health experts and proponents of PEPFAR have said the cuts will have a devastating impact on HIV/AIDS prevention and treatment. It would endanger access to lifesaving antiretroviral medication and put millions of children and adults at risk. The White House wants to phase down its investment in PEPFAR and have other countries absorb most of the cost. 'It is something that our budget will be very trim on because we believe that many of these nonprofits are not geared toward the viewpoints of the administration, and we're $37 trillion in debt,' White House budget director Russ Vought told appropriators last week. 'So, at some point, the continent of Africa needs to absorb more of the burden of providing this health care.' Advocates agree the program wasn't meant to last forever, but the groundwork hasn't been done to make sure PEPFAR can be transitioned successfully. The White House plan would cut off funding without a plan. But the Senate will have the final say on how sweeping the clawbacks are. Congress has 45 days to act, and not every Republican senator is on board. Senate Appropriations Committee chair Susan Collins (R-Maine) has said she is opposed to PEPFAR cuts, and others have expressed concern about the other funding cuts in the package, like public broadcasting programs. Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Prenatal exposure to 'forever chemicals' may raise blood pressure during teen years: Study Humans exposed to toxic 'forever chemicals' before birth may exhibit higher blood pressure during their teenage years, a new study has found. This connection was particularly pronounced in boys and in children born to non-Hispanic Black mothers, scientists observed in the study, published Thursday in the Journal of the American Heart Association. While previous research has shown these synthetic compounds may affect a rapidly … CDC backtracks, will rehire more than 450 people it laid off The Centers for Disease Control and Prevention (CDC) is rehiring about 460 employees who had previously been laid off, according to an email notice reviewed by The Hill. The Department of Health and Human Services (HHS) confirmed on Thursday that reinstatement notices were sent but provided few other details. 'The Trump Administration is committed to protecting essential services—whether it's supporting coal … Trump's former surgeon general rips RFK Jr.'s purge of vaccine board President Trump's former surgeon general blasted Health and Human Services Secretary Robert F. Kennedy Jr.'s decision to fire the entirety of a federal advisory committee on vaccine guidance, saying the move jeopardizes public health and threatens public trust in health institutions. In an op-ed published by Time, former Surgeon General Jerome Adams wrote that Kennedy's recent actions cast doubt over his pledge … In Other News Branch out with a different read: Cassidy in a bind as RFK Jr. blows up vaccine policy Health and Human Services Secretary Robert F. Kennedy Jr. has put Sen. Bill Cassidy (R-La.) in a political bind, squeezed by his loyalty to President Trump and commitment to medicine. Cassidy, the chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, publicly wavered over Kennedy's confirmation, sharply criticizing his views before eventually voting for him. Cassidy said he secured a series … Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: Republicans lay groundwork for 'total tax cliff' at end of Trump's term Congressional Republicans are laying the groundwork for a tax cliff at the end of President Trump's term in office. While the conference is pushing … Read more Padilla forcibly removed from Noem press conference, handcuffed Sen. Alex Padilla (D-Calif.) was forcibly removed and then handcuffed after he interrupted a press conference Homeland Security Secretary Kristi Noem … Read more What People Think Opinion related to health submitted to The Hill: You're all caught up. See you tomorrow! Thank you for signing up! Subscribe to more newsletters here
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Premature baby dies with measles
As measles cases across Elgin County and North America continue to rise, a southwestern Ontario infant infected by its unimmunized mother was identified June 5 as Canada's first death related to a measles outbreak that took hold of the nation on Oct. 30, 2024. 'It is with deep sadness that I confirm that an infant, born prematurely and infected with measles, has tragically passed away in southwestern Ontario,' Dr. Kieran Moore, Ontario's Chief Medical Officer of Health said in a statement. Dr. Moore said the infant contracted the virus before birth from the unimmunized mother. While measles may have been a contributing factor in both the premature birth and death, Dr. Moore said that the infant also faced other serious medical complications unrelated to the virus. 'Anyone who is unvaccinated is at risk and I urge everyone, but especially those who may become pregnant, to ensure they have received two doses of the MMR (measles, mumps, and rubella) vaccine, which will protect both a parent and baby,' added Dr. Moore. 'This vaccine has been safely used for over 50 years and is highly effective.' Dr. Ninh Tran, Southwestern Public Health's Medical Officer of Health added: 'This event underscores the seriousness of measles in pregnant individuals, as it can cause low birth weight for the baby, preterm birth, and miscarriage. 'Measles can also cause pneumonia, brain swelling, and death, with infants and immunocompromised individuals especially vulnerable to these risks,' Dr. Tran said in a separate statement. 'The safest and most effective way to protect yourself from measles is through immunization.' The United States has reported 1,088 cases this year, as of June 1, according to a Reuters report. Two children have died in the Texas outbreak. The Government of Canada's latest report shows there are 2,755 measles cases in nine jurisdictions, as of May 24, 2025. That's an increase of 244 measles cases since the previous report. As of June 3, 2025, Ontario has reported a total of 2,009 measles cases in 19 public health units, an increase of 121 cases since the previous week. The weekly provincial report indicates 74.9 percent of measles case in Ontario were infants, children and adolescents, while 24.5 percent were adults. More than 96 percent of all infant, child and adolescent outbreak cases were unimmunized, while 67.3 of adults were unimmunized. A total of 1.9 percent of all cases were pregnant women, with 74.4 percent unimmunized. Six cases of congenital measles, infants diagnosed in the first 10 days of life, have been identified since the Ontario outbreak began on October 30, 2024. SWPH reported 727 cases in the region from Oct 30, 2024 to June 5, 2025, 10 more measles cases since May 29, 2025. More than 74 percent of cases are 18 years old or younger. Nearly 89 percent of cases were unimmunized people. According to the World Health Organization (WHO), before widespread measles vaccinations were available in 1963, major epidemics occurred about every two-to-three years, causing an estimated 2.6 million deaths each year. An estimated 107,500 people died from measles in 2023. Accelerated immunization activities prevented an estimated 60 million deaths from 2000 to 2023, according to WHO. Vaccinations decreased estimated measles deaths from 800,062 in 2000 to 107,500 in 2022. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
2 hours ago
- Yahoo
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January. Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial. Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone. The company has launched a new late-stage trial for the drug, the U.S. government's trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies. Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly may be gaining an edge over the company in the market for such drugs.
